Effect of panel-reactive antibody in predicting crossmatch selection of cadaveric kidney recipients

被引:28
作者
Lieber, S. R.
Perez, F. V. T.
Tabossi, M. R.
Persoli, L. B. L.
Marques, S. B. D.
Mazzali, M.
Alves-Filho, G.
de Souza, C. A.
机构
[1] Univ Estadual Campinas, Hematol & Hemotherapy Ctr, Sao Paulo, Brazil
[2] Univ Estadual Campinas, Dept Clin Med, Sao Paulo, Brazil
关键词
D O I
10.1016/j.transproceed.2007.01.045
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Aim. The influence of panel-reactive antibody level (%PRA) on crossmatch results was evaluated among 866 patients on the waiting list for cadaveric renal allografting from January 2001 to August 2005. We evaluated the results for 124 potential donors for a kidney, including 2008 crossmatches. Four hundred eighteen patients were tested against only 1 donor. Methods. Serum samples were screened for anti-HLA antibodies using immunoglobulin (Ig)G enzyme-linked immunosorbent assay (ELISA) PRA kit and the %PRA of the most reactive sample (peak) was used for patient stratification, according to sensitization level. Crossmatches were performed on fresh donor T lymphocytes from peripheral lymph nodes, using classical and anti-human-globulin enhanced complement-dependent cytotoxicity (CDC-T) methods. The tests were performed using peak and current patient sera before and after dithiothreitol treatment. The crossmatch was assumed to be negative when no reactivity was observed in all tests. Results. The incidences of positive crossmatch were as follows: 72.3%,14.6%, and 7.2%, among patients with PRA > 50%, PRA :<= 50%, and PRA = 0%, respectively. A negative crossmatch was observed in 6.5% (4 of 62) of the tests among 100% PRA patients. Conclusion. Although %PRA level reflects the HLA sensitization of the patient, IgG ELISA PRA and CDC-T crossmatch may not reflect the same antibodies, and both results must be considered in a transplantation decision.
引用
收藏
页码:429 / 431
页数:3
相关论文
共 17 条
  • [1] Impact of the delayed graft function in hypersensitized kidney transplant patients
    Arias, M
    [J]. TRANSPLANTATION PROCEEDINGS, 2003, 35 (05) : 1655 - 1657
  • [2] Detection and specification of noncomplement binding anti-HLA alloantibodies
    Arnold, ML
    Zacher, T
    Dechant, M
    Kalden, JR
    Doxiadis, IIN
    Spriewald, BM
    [J]. HUMAN IMMUNOLOGY, 2004, 65 (11) : 1288 - 1296
  • [3] IgM antibodies identified by a DTT-ameliorated positive crossmatch do not influence renal graft outcome but the strength of the IgM lymphocytotoxicity is associated with DR phenotype
    Bryan, CF
    Martinez, J
    Muruve, N
    Nelson, PW
    Pierce, GE
    Ross, G
    Shield, CF
    Warady, BA
    Aeder, MI
    Harrell, KM
    Helling, TS
    Luger, AM
    [J]. CLINICAL TRANSPLANTATION, 2001, 15 : 28 - 35
  • [4] de Capei MU, 2002, EUR J IMMUNOGENET, V29, P379
  • [5] Detection of donor-specific antibodies using HLA-coated microspheres: another tool for kidney transplant risk stratification
    Gibney, Eric M.
    Cagle, Linda R.
    Freed, Brian
    Warnell, Stephanie E.
    Chan, Larry
    Wiseman, Alexander C.
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2006, 21 (09) : 2625 - 2629
  • [6] Standardization of cellular immunoenzyme assay for anti-HLA class I antibodies evaluation: Comparison with complement-dependent cytotoxicity methods
    Lieber, SR
    Beck, ST
    Persoli, LBL
    Mazzali, M
    [J]. TRANSPLANTATION PROCEEDINGS, 1999, 31 (07) : 2989 - 2993
  • [7] Lietz Katarzyna, 2003, Ann Transplant, V8, P17
  • [8] Clinical relevance of low levels of preformed alloantibodies detected by flow cytometry in the first year post-kidney transplantation
    Michelon, T
    Schroeder, R
    Fagundes, I
    Canabarro, R
    Sporleder, H
    Rodrigues, H
    Silveira, J
    Montagner, J
    Garcia, V
    Neumann, J
    Graudenz, M
    [J]. TRANSPLANTATION PROCEEDINGS, 2005, 37 (06) : 2750 - 2752
  • [9] Non-HLA transplantation immunity revealed by lymphocytotoxic antibodies
    Opelz, G
    [J]. LANCET, 2005, 365 (9470) : 1570 - 1576
  • [10] OPELZ G, 1999, REV IMMUNOGENET, V1, P344